Safety and Efficacy Study of IMSA101 in Refractory Malignancies
Public ClinicalTrials.gov record NCT04020185. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Open-label, dose escalation (Phase I) and dose expansion (Phase IIA) study of patients receiving intra-tumoral IMSA101 alone or in combination with an immune checkpoint inhibitor (ICI) (Phase I and II)
Study identification
- NCT ID
- NCT04020185
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Interventions
- IMSA101 Drug
- Immune checkpoint inhibitor (ICI) Drug
- Immuno-oncology (IO) therapy Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 22, 2019
- Primary completion
- Sep 14, 2023
- Completion
- Sep 14, 2023
- Last update posted
- Dec 10, 2024
2019 – 2023
United States locations
- U.S. sites
- 6
- U.S. states
- 5
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Honor Health | Scottsdale | Arizona | 85260 | — |
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Atlantic Health System/Morristown Medical Center | Morristown | New Jersey | 07962 | — |
| UT Southwestern | Dallas | Texas | 75390 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Solid Tumor, Adult trials
Other public records listing Solid Tumor, Adult. Sorted by last update posted; newest first. Not a recommendation.
- NCT04243499: First-in-Human Study of ICT01 in Patients With Advanced Cancer Active, not recruiting
- NCT06265688: First In Human Study of CX-2051 in Advanced Solid Tumors Recruiting
- NCT06824363: ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu Recruiting
- NCT04942717: Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values Recruiting
- NCT04673942: A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors Active, not recruiting
- NCT04219254: A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04020185, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 10, 2024 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04020185 live on ClinicalTrials.gov.